National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Ticagrelor (Brilique®)

Ticagrelor (Brilique®) 60mg, co-administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with acute coronary syndromes (ACS) or a history of myocardial infarction (MI) and a high risk of developing an atherothrombotic event.

Rapid Review

Commenced Completed Outcome
29/02/2016 04/05/2016 Full Pharmacoeconomic Evaluation Recommended

 Not considered cost-effective due to non-submission of full pharmacoeonomic evaluation